USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Sumitomo Pharma Switzerland GmbH

USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Sumitomo ranks #37,732 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 4 technology areas.

#37,732
of 49,997 US assignees by volume
Top 20%
by Innovation Score (46.9/100)
21.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R37732 · Foreign Corporation #37,732 · 7 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 7 grants
  • LOWER-Q #37,732/49,997
  • PHOTO-FINISH Sucxess
  • CPC-NARROW A61P · 4 areas
  • INNOV-PAR 46.9/100
  • CLAIMS-DENSE 21.0 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2023–2025 · 3y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Sucxess LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Sumitomo

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Sumitomo's Innovation Score is 46.9/100 (top 20% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Sumitomo's grants concentrate

Sumitomo Pharma Switzerland GmbH is a focused PatentsView assignee: 4 CPC subclasses with 85.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (4 grants) versus a trough of 1 in 2023. By volume, Sumitomo sits between Sucxess LLC and Superba S.A.S..

Sumitomo's three-year grant acceleration

Sumitomo Pharma Switzerland GmbH shows 5 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Sumitomo's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Sumitomo holds 7 patents at rank #37,735, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Sumitomo

By rank, the assignees closest to #37,735 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Sumitomo's primary technology class.

Sumitomo's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

47 Top 20% higher than 80% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 202320242025 2
USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table
Sumitomo Pharma Switzerland GmbH patent grants by year, 2015–2025
Year Patents Granted Share of Period
2023 1 14.3%
2024 4 57.1%
2025partial year 2 28.6%

Where it ranks

Overall rank by patents

#37,732

of 49,997 tracked assignees

Innovation Score

46.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Sumitomo Pharma Switzerland GmbH's patent record in context - here's where to go next.

  • Sumitomo Pharma Switzerland GmbH's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 85.7% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #37,732 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Sumitomo Pharma Switzerland GmbH against Sucxess LLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 46.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.